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During the course of Chagas disease, infectious forms of Trypanosoma cruzi are 
occasionally liberated from parasitized heart cells. Studies performed with tissue cul-
ture trypomastigotes (TCTs, Dm28c strain) demonstrated that these parasites evoke 
neutrophil/CXCR2-dependent microvascular leakage by activating innate sentinel cells 
via toll-like receptor 2 (TLR2). Upon plasma extravasation, proteolytically derived kinins 
and C5a stimulate immunoprotective Th1 responses via cross-talk between bradykinin 
B2 receptors (B2Rs) and C5aR. Awareness that TCTs invade cardiovascular cells in vitro 
via interdependent activation of B2R and endothelin receptors [endothelin A receptor 
(ETAR)/endothelin B receptor (ETBR)] led us to hypothesize that T. cruzi might reciprocally 
benefit from the formation of infection-associated edema via activation of kallikrein–
kinin system (KKS). Using intravital microscopy, here we first examined the functional 
interplay between mast cells (MCs) and the KKS by topically exposing the hamster 
cheek pouch (HCP) tissues to dextran sulfate (DXS), a potent “contact” activator of 
the KKS. Surprisingly, although DXS was inert for at least 30 min, a subtle MC-driven 
leakage resulted in factor XII (FXII)-dependent activation of the KKS, which then amplified 
inflammation via generation of bradykinin (BK). Guided by this mechanistic insight, we 
next exposed TCTs to “leaky” HCP—forged by low dose histamine application—and 
found that the proinflammatory phenotype of TCTs was boosted by BK generated via 
the MC/KKS pathway. Measurements of footpad edema in MC-deficient mice linked 
TCT-evoked inflammation to MC degranulation (upstream) and FXII-mediated generation 
of BK (downstream). We then inoculated TCTs intracardiacally in mice and found a 
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striking decrease of parasite DNA (quantitative polymerase chain reaction; 3 d.p.i.) in the 
heart of MC-deficient mutant mice. Moreover, the intracardiac parasite load was signifi-
cantly reduced in WT mice pretreated with (i) cromoglycate (MC stabilizer) (ii) infestin-4, 
a specific inhibitor of FXIIa (iii) HOE-140 (specific antagonist of B2R), and (iv) bosentan, 
a non-selective antagonist of ETAR/ETBR. Notably, histopathology of heart tissues from 
mice pretreated with these G protein-coupled receptors blockers revealed that myocar-
ditis and heart fibrosis (30 d.p.i.) was markedly and redundantly attenuated. Collectively, 
our study suggests that inflammatory edema propagated via activation of the MC/KKS 
pathway fuels intracardiac parasitism by generating infection-stimulatory peptides (BK 
and endothelins) in the edematous heart tissues.
Keywords: bradykinin, chagas disease, endothelin, g protein-coupled receptors, kallikrein, mast cells, 
Trypanosoma cruzi
inTrODUcTiOn
Although the complement system is a classic example of a proteo-
lytic cascade that stimulates immunity through the generation of 
proinflammatory peptides, studies in different infectious disease 
models extended this concept to the kallikrein–kinin system 
(KKS) (1). Intravascular activation of the KKS is initiated when 
the zymogen factor XII (FXII) interacts with a broad range of 
endogenous “contact” substances (2), including negatively 
charged polymers, such as platelet-derived polyphosphates 
(polyP) (3) and DNA associated with neutrophil extracellular 
traps (4). Trace formation of FXIIa in the blood is sufficient to 
convert the prekallikrein into active plasma kallikrein (PKa), a 
serine protease that reciprocally cleaves FXII. Feedback cycles of 
activation between PK/FXII lead to FXIIa-mediated cleavage of 
FXIa. Further downstream, FXIa generates FIXa—the effector 
of fibrin formation via the intrinsic pathway of coagulation. In 
parallel, PK activates the proinflammatory KKS by proteolytically 
excising bradykinin (BK) from an internal moiety of high molec-
ular weight kininogen (HK). Acting as a paracrine mediator, the 
short-lived BK induces vasodilation and increases microvascular 
permeability via activation of endothelial bradykinin B2 receptor 
(B2R), a constitutively expressed subtype of kinin receptor (5). 
In addition, PK promotes plasmin-dependent fibrinolysis and 
C3 activation, hence couples FXIIa-dependent thrombogenesis 
to fibrinolytic and immunological mechanisms. As inflamma-
tion persists, a GPI-linked carboxypeptidase M removes the 
C-terminal arginine from the primary kinin, thus converting the 
B2R agonist into a high-affinity ligand for bradykinin B1 receptor 
(B1R) (6), a G protein-coupled receptor (GPCR) subtype that is 
transcriptionally upregulated in injured tissues by proinflam-
matory cues, such as IL-1β, TNF-α (7, 8), or by prooxidative 
polypeptides, e.g., angiotensin II and endothelin-1 (ET-1) (9).
During infection or sterile inflammation, subtle increases in 
endothelial permeability allow for the extravascular accumula-
tion/diffusion of plasma proteins, including complement com-
ponents and blood-borne kininogens (high or low molecular 
weight) (1). Using animal models of severe MC-mediated allergic 
reactions, Sala-Cunill et al. (10) showed that BK fueled inflamma-
tion via mechanisms involving activation of FXII by endogenous 
contact factors released from MC granules, e.g., heparin (11) 
and/or PolyP (12). Once liberated by PK, the short-lived BK 
rapidly potentiates allergic inflammation via iterative cycles of 
B2R-dependent activation of the endothelium and plasma leak-
age. During infection, kinins can be released extravascularly by 
the action of microbial kininogenases, such as cruzipain and 
gingipains, i.e., cysteine proteases respectively expressed by the 
parasitic protozoan Trypanosoma cruzi (13) and the periodontal 
bacteria Porphyromonas gingivalis (14, 15), both of which object 
of systematic investigations in vitro and in vivo.
Afflicting approximately 8 million people in Latin America 
(16), Chagas disease, the heart pathology caused by chronic 
T. cruzi infection, remains incurable (17). Human infection 
starts when the blood seeking triatomine releases infective 
forms (metacyclic trypomastigotes) on tissues lacerated by the 
proboscis. Alternatively, T. cruzi is transmitted orally following 
ingestion of macerated fruit juices that were contaminated with 
infected bugs (18, 19). The life cycle of T. cruzi in mammals 
requires an obligate stage of intracellular development in a broad 
range of host cells, including epithelial cells, tissue-resident 
macrophages, and cardiomyocytes. After invading host cells via 
a mechanism akin to endocytosis, the trypomastigotes rapidly 
escape from parasitophorous vacuole and reach the host cell 
cytoplasm, where they transform into oval-shaped amastigotes 
(replicating forms). After coopting the host cell metabolism to 
support amastigote division for several days (20), the amastigotes 
transform into infective trypomastigotes. Upon cell death, the 
extracellular trypomastigotes navigate away from the primary 
foci of infection and enter the bloodstream from where the infec-
tion is disseminated. Characterized by high blood parasitemia 
and systemic inflammation, acute Chagas disease subsides with 
the onset of adaptive immunity. However, a low-grade infection 
(asymptomatic) persists for several years before development 
of clinical symptoms. Although a minority of patients present 
Abbreviations: BK, bradykinin; B1R, bradykinin B1 receptor; B2R, bradykinin 
B2 receptor; HK, high molecular weight kininogen; LK, low molecular weight 
kininogen; LBK, lysyl-BK; GPCR, G protein-coupled receptor; ACE, angiotensin-
converting enzyme; PKa, plasma kallikrein; KKS, kallikrein–kinin system; FXII, 
coagulation factor XII; MCs, mast cells; CCC, chronic chagasic cardiomyopathy; 
HCP, hamster cheek pouch; ET-1, endothelin-1; ETAR, endothelin A receptor; 
ETBR, endothelin B receptor; DXS, dextran sulfate; TCTs, tissue culture trypomas-
tigotes; H1R, histamine H1 receptor; polyP, polyphosphates.
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digestive system complications (megacolon), about 25% of the 
chronically infected chagasic patients develop a progressive and 
as yet incurable cardiomyopathy [chronic chagasic cardiomyo-
pathy (CCC)] (21).
Clinical and histopathological studies in T. cruzi-infected mice 
have linked severity of CCC to immunoregulatory abnormalities 
(22). Systematic investigations in mice models of chronic Chagas 
disease indicated that chronic myocarditis/fibrosis worsens as a 
consequence of an imbalance between protective versus patho-
genic subsets of heart-infiltrating IFN-γ and perforin-producing 
CD8+ T cells (23). More recently, cohort studies performed in 
Spain revealed that chronic chagasic patients display a hyper-
coagulopathy phenotype (24). Although the role of the contact 
system was not explored in this particular study, these findings 
raise the possibility that, over the years, activated monocytes cir-
culating in the bloodstream of chronic chagasic patients might 
forge the coupling between the extrinsic/intrinsic pathways of 
coagulation (1). While not excluding a primary role for infection-
associated immunopathology (25), it was reported that patients 
with chronic myocardiopathy display marked abnormalities 
in heart microvessels and extracellular matrix. Insight on the 
molecular basis of CCC emerged from experimental studies 
(26) showing that parasitized cardiomyocytes upregulate the 
expression of ET-1, a potent vasoconstrictor and profibrosing 
polypeptide. Extending this analysis to in  vivo setting, these 
authors showed evidence that heart fibrosis was attenuated in 
transgenic mice in which ET-1 was genetically ablated from 
cardiomyocytes—but not from endothelial cells. While these 
studies were in progress, our group suggested that generation 
of kinins may have a dual role in host/parasite equilibrium 
(27). Acting on the behalf of host defenses, the released kinins 
stimulate B2R expressed by immature dendritic cells (28), hence 
convert these antigen-presenting cells into inducers of IFN-γ-
producing (immunoprotective) effector CD4 and CD8 T  cells 
(29–31). Although limited to in vitro studies, the hypothesis that 
T. cruzi might reciprocally benefit from the activation of the KKS 
(27) was initially supported by evidence that tissue culture try-
pomastigotes (TCTs) (Dm28c strain) invade non-professional 
phagocytic cells (e.g., smooth muscle cells and cardiomyocytes) 
via cross-talk between B2R, B1R and endothelin receptors 
[endothelin A receptor (ETAR)/endothelin B receptor (ETBR)] 
(13, 27, 32, 33). Using multiple infection models, here we 
demonstrate that inflammatory edema propagated via the MC/
KKS pathway fuels heart parasitism and worsens myocarditis/
fibrosis by generating infection-promoting peptides, such as 
kinins and endothelins. Our study illustrates how endothelial 
barrier destabilization, a common manifestation of inflam-
mation, might provide T. cruzi with an opportunity to rapidly 
invade surrounding host cells, hence ultimately escaping from 
humoral immunity.
MaTerials anD MeThODs
ethics statement
All animal care and experimental procedures were performed 
in accordance to the Brazilian guidelines (Brazilian Directive 
for Care and Use of animals for Teaching and Research—
DBCA) published by the Brazilian Council for Control of 
Animal Experimentation (Conselho Nacional de Controle de 
Experimentação Animal—CONCEA, http://www.mct.gov.br/
upd_blob/0234/234054.pdf) and Federal Law 11.794 (October 
8, 2008). Studies involving animals are reported in compliance 
with the ARRIVE guidelines (34, 35). The protocols used in this 
study were approved by the Institutional Ethical Committee of 
Federal University of Rio de Janeiro (code number: IBCCF 101, 
and license protocol number 014).
Mice inbred strains
Colonies of C57BL/6 and BALB/c were purchased from our 
facilities (UFRJ, Rio de Janeiro). B6-Kit+/+ (wild type) and 
B6-KitW-sh/W-sh (MC-deficient) were provided by one of the 
co-authors (M.A.; UFMG, Belo Horizonte). The experiments 
were conducted with male or female mice, 8- to 12-weeks-old, 
weighting 20–25 g and housed in ventilated cages under specific 
pathogen-free conditions, in our animal facilities at 22 ± 2°C with 
a 12 h light dark cycle, with access to food (normal diet) and water 
ad libitum. Mice were randomly allocated to each experimental 
group.
antibodies and reagents
FITC–dextran 150 kDa and dextran sulfate (DXS) 500 kDa were 
purchased from TdB Consultancy (Uppsala, Sweden). Heparin 
4  kDa (enoxaparin EUROFARMA Versa, NC 154693) was 
kindly provided by PAS Mourão (Universidade Federal do Rio 
de Janeiro). HOE-140, B2R antagonist (B2RA) was purchased 
from Sigma (St. Louis, MO, USA). Bosentan was a donation from 
Actelion (Basel, Switzerland). FXII inhibitor (36) was a generous 
gift from Dr. Thomas Renné (Karolinska Institute). Cromoglycate, 
mepyramine, histamine, captopril were purchase from Sigma 
(St. Louis, MO, USA). PKSI-527 and PdSP15a were supplied by 
the co-authors (LJ) and (PA), respectively.
generation of TcTs
Tissue culture trypomastigotes (Dm28c, originally a gift from 
Dr. Samuel Goldenberg, Instituto Carlos Chagas, Fiocruz, Parana) 
were harvested from the supernatants of cultures of monkey 
kidney fibroblast cell line LLC-MK2 (American Type Culture 
Collection—CCL-7) 5  days after infection. The cultures were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM), 2% 
heat inactivated fetal calf serum (FCS). The freshly released TCTs 
were washed twice with excess Hank’s Balanced Saline Solution 
(HBSS) before being tested in vitro or in vivo, as described below.
cell culture
Mouse heart cells were isolated in the laboratory of one of the 
co-authors (MS) as previously described (37) and seeded on cov-
erslips laid in 24-well plates. Primary cultures of mice embryonic 
heart cells were maintained at 37°C in 5% CO2 atmosphere in 
DMEM, 10% FCS to get synchronized contractility.
invasion assays
Tissue culture trypomastigotes were added to monolayers of 
primary heart cells (parasite ratio of 1:1) in DMEM containing 
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1 mg/ml human serum albumin (HAS—Baxter Pharmaceutical, 
Deerfield, IL, USA). Where indicated, the DMEM-HSA medium 
was supplemented with the angiotensin-converting enzyme 
(ACE) inhibitor lisinopril (25  µM) and/or the following com-
pounds (isolated or combined): HOE-140 (B2RA) (0.1 µM), or 
cromoglycate (140  µg/ml). Stock solutions of HOE-140 were 
prepared in apyrogenic water and cromoglycate in PBS. Optimal 
concentration of HOE-140 was defined based on dose–response 
curves reported elsewhere (33). Host/parasite interactions pro-
ceeded for 3 h at 37°C in a humidified incubator, in a 5% CO2 
atmosphere. At the end point of the assay, the infected monolay-
ers were washed three times with HBSS, fixed in Bouin and 
staining with Giemsa. The infection was determined by counting 
the number of intracellular parasites in a total of 100 cells per 
coverslip. Assays were performed in triplicates.
Paw edema Measurements
B6-Kit+/+, B6-kitW-sh/W-sh, and BALB/c mice, under ketamine 
and xilazyne anesthesia (80 and 8  mg/kg, respectively), were 
injected into the hind footpad with Dm28c TCTs (106 parasites 
in 10 µl of PBS) or with PBS (contralateral paw as a control). 
The sequential measurement of test and contralateral paws 
allows each mouse to serve as its own control, thus reducing 
animal use. Altogether, 165 mice were used. These assays were 
performed as previously described (29, 31, 38). Where indi-
cated, animals were pretreated (−1 h) with a single-dose of ACE 
inhibitor captopril (4 mg/kg, i.p.) to minimize the degradation 
of kinins; HOE-140 (100  µg/kg—s.c.); cromoglycate (20  mg/
kg—i.v.); histamine H1 receptor (H1R) antagonist mepyramine 
(10 mg/kg—i.p.), or infestin-4 (FXII inhibitor; 4.5 mg/kg—i.v.). 
Paw volume (3 h p.i. or 24 h p.i.) was measured with the aid of a 
plethysmometer. In the interval between measurements of 3 and 
24 h, animals were housed following the conditions described 
above (Mice inbred strains). At the end of the experiments, 
mice were euthanized by CO2 inhalation. The data obtained 
were expressed as difference in volume (microliters) between 
the test and control paws.
Microvascular Permeability 
Measurements—intravital Digital 
Microscopy
Hamsters were purchased from Anilab (São Paulo, Brazil) and 
maintained in our animal facilities. The experiments were con-
ducted with male hamsters, 3 months old, weighting 110–120 g. 
Altogether, 134 hamsters were used and the procedures were 
approved by the local ethical committee (IBCCF, license protocol 
number 014). Animals were anesthetized by injection of sodium 
pentobarbital (i.p.) supplemented with α-chloralose (2.5% W/V, 
solution in saline, i.v.) through a femoral vein catheter as previously 
described (39, 40). During the experimental procedures anesthe-
sia was monitored by reflex measurement and supplemented with 
α-chloralose (2.5% W/V, solution in saline, i.v.) through a femoral 
vein catheter whenever required. A tracheal cannula (PE 190) 
was inserted to facilitate spontaneous breathing and the body 
temperature was maintained at 37°C by a heating pad monitored 
with a rectal thermistor. The hamster cheek pouch (HCP) was 
prepared for intravital microscopy (IVM) as reported (14, 39). 
The microcirculation of the HCP was observed after intravenous 
injection of the tracer FITC-dextran 150 kDa (100 mg/kg) using 
an Axioskop 40 microscope, objective 4× and oculars 10× (Carl 
Zeiss, Germany), equipped with appropriate filter (490/520 nm) 
for observations of fluorescence in epiluminescence (Colibri 2, 
Carl Zeiss, Germany). HCPs were continuously superfused with 
a HEPES-bicarbonate-buffered saline solution (pH 7.4; compo-
sition in mM: 110.0 NaCl, 4.7 KCl, 2.0 CaCl2, 1.2 MgSO4, 18.0 
NaHCO3, 15.39 HEPES, and 14.61 Na HEPES) at a constant rate 
of 5  ml/min. A digital camera, AxioCamHRc, and a computer 
with the AxioVision 4.4 software program (Carl Zeiss) were used 
for image analysis of arteriolar diameter and total fluorescence in a 
representative rectangular area (5 mm2) of the HCP. The recorded 
fluorescence at 30 min after FITC-dextran injection [relative fluo-
rescence units (RFUs)] in each experiment was adjusted to 2,000 
RFU for statistical reasons. After an initial 30 min control period 
of continuous superfusion to verify normal microvascular flow in 
all vessels and absence of plasma leakage, HCPs were subjected 
to topical applications of different combinations of treatments, 
either added to superfusion solution or during interrupted 
superfusion in 500 µl of saline on top of the HCP-tissue. After 
the periods of interrupted superfusion, the flow was restarted. 
In a first group of experiments, HCPs were exposed to DXS 
500 kDa (DXS—0.4, 2, or 4 µM) followed, or not, by application 
of histamine (4 µM), or by application of heparinized (heparin 
4 kDa) hamster plasma (50 µl). In the second protocol, the HCP 
(steady state) was superfused for 10 min with captopril (10 µM) 
solution prior to the topical application of TCTs (3 × 107) in the 
presence or absence of histamine (4 µM). At 60 min after topical 
application of TCTs, the HCPs were stimulated with histamine 
for 5 min as an internal control of normal reactivity of the micro-
vasculature. Pharmacological interventions were carried out with 
cromoglycate (MC stabilizer, 40  mg/kg, i.p.), captopril (ACE 
inhibitor, 10  µM), HOE-140 (B2RA; 0.5  µM), PKSI-527 (PKa 
inhibitor, 20  µM) (41), and PdSP15a (contact phase inhibitor, 
20 µM) (42). Dose–response experiments involved superfusion 
of HCPs for 10 min with captopril (10 µM) solution prior to the 
topical application of 60, 600, 6,000, and 60,000 TCTs/μl in 500 µl 
together with histamine 4 µM that were followed by histamine 
alone (4 µM) for 5 min at 60 min after TCT-application. At the 
end of each experiment, animals were euthanized by an overdose 
of pentobarbital and an i.v. injection of KCl 3 M.
contact system activation
The activation of FXII/PK in citrated hamster plasma-treated (or 
not) with DXS 500 kDa was monitored by spectrofluorimetry as 
previously described (42, 43) using internally quenched fluores-
cent substrates whose sequences correspond to the C-terminal 
(Abz-GFSPFRAPRVQ-EDDnp) flanking region of BK of rat kini-
nogen. The reaction was carried out in PBS, pH 7.4, using citrated 
hamster plasma (5%, v/v) or heparin (4 kDa), 4 µM of the Abz-
peptidyl-EDDnp substrate, and 4 or 20 nM of the contact system 
activator DXS (500 kDa), at 37°C. The synthetic PKa inhibitor 
(PKSI-527, 10 µM) (41) was preincubated with hamster plasma 
for 5 min, at 37°C, prior to the addition of DXS and the substrate. 
The hydrolysis of the cleaved substrate Abz-peptidyl-EDDnp 
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(Abz  =  O-aminobenzoyl and EDDnP  =  ethylenediamine 
2,4-dinitrophenyl) was monitored by measuring the fluorescence 
at λex = 320 nm and λem = 420 nm in a fluorescence spectro-
photometer (Spectramax M5–Molecular Device). Citrated or 
heparinized plasma (platelet free) was prepared by centrifugation 
of blood samples at 2,500 × g for 20 min at 4°C and quickly stored 
at −80°C in polypropylene tubes before use. After centrifugation, 
plasma samples were filtered using a 0.2 µm membrane.
echo-guided intracardiac injection
Mice were trichotomized using a commercial depilatory gel. The 
animals were positioned at a holder that has conductive plates, 
enabling echocardiogram registration on the chest covered with 
ultrasound gel by means of a VisualSonic VEVO device 770 with 
30-MHz transducer. The procedure was done under anesthesia 
provided by an isoflurane gas outlet while maintaining the tem-
perature at 40°C. Heart was visualized in cross section in height 
of the papillary muscles lines and a needle was aligned with the 
transducer to display it near the left ventricular cavity. The aligned 
needle penetrated the myocardium, and after aspiration to verify 
if the cavity was accessed, we injected the suspension of Dm28c 
TCTs (106 parasites) or PBS solution (volume of 50  µl) in the 
myocardium [lateral wall of the left ventricle (LV)]. After being 
removed from the holder, the animals were left in their cages where 
they recover from anesthesia within 5 min. Furthermore, animals 
were housed following the conditions described above (Mice 
inbred strains). At the end of the study, mice were euthanized by 
CO2 inhalation followed by the assessment of heart parasite load 
and histological analyses. Altogether, 180 mice were used.
histopathological analyzes of heart 
Tissues
The heart tissues from C57BL/6 mice infected as described above 
were isolated at 30 d.p.i and processed for evaluation of leukocyte 
infiltrates, MCs, and collagen deposition. Hearts were removed, 
washed, and softly squeezed in PBS until expel the blood before 
being fixed in formalin 5% for 24 h at room temperature. Hearts 
(cutting in half) were transferred to the tissue cassette and dehy-
drated through serial EtOH incubation for 30  min. They were 
then clarified in xylene (three times) for 30 min each. After 1 h in 
Erv-plast paraffin (Easypath-Brazil) at 58°C, hearts were embed-
ded in the same paraffin. Serial sections (4  µm) were cut and 
after removal of the paraffin, they were incubated in serial EtOH 
followed by staining with H&E, Safranin, or Picrosirius Red, to 
evaluate respectively infiltrating leukocytes, MCs, and collagen 
fibers. Sections were visualized using a LEICA scan microscope 
with 20× objective (H&E, Safranin), and 20× or 10× objective 
(Picrosirius Red). Hearts from non-infected mice (PBS injected) 
were always included as controls and did not exhibit pathologic 
changes. Leukocyte infiltration was quantified by counting (±200 
cells in 50 fields) in the entire pericardium area and myocardium 
near pericardium, where they were preferentially localized. 
Cardiac MCs were quantified by counting Safranin positive cells 
in the pericardium and near the pericardium area. For collagen 
quantification, six sections of one of the halves were entirely pho-
tographed. Using Image Pro-Plus (Image Processing and Analysis 
Software), we measured each photographed section and adjust 
as total area. The percentage of collagen area was calculated in 
relation to the total area.
Measurements of T. cruzi Dna in the 
Mouse Tissues
Trypanosoma cruzi quantification was performed as previously 
described by our group (30) and others (44). C57BL/6, B6-Kit+/+, 
and B6-kitW-sh/W-sh mice were infected according to the 
description above. Where indicated, the animals were treated 
1  h prior to infection with a single-dose of: (i) cromoglycate 
(20 mg/kg—i.v.), (ii) B2R antagonist HOE-140 (100 µg/kg—s.c.), 
(iii) ETAR/ETBR double antagonist Bosentan (30  mg/kg—i.p.) 
(45), or (iv) FXII inhibitor (4.5 mg/kg—i.v.) (36). Hearts were iso-
lated 3 d.p.i., washed, softly squeezed in PBS until expel the blood 
and minced with surgical blades before DNA was isolated using 
the DNeasy blood and tissue Kit (QIAGEN) or PureLink genomic 
DNA mini Kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Briefly, up to 25  mg of tissue was 
added to a 2 ml sample tube with lysis Buffer and proteinase K, 
mixed by gentle vortex and, subsequently, incubated at 56°C for 
3 h. The DNA concentration was determined using the NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies). The 
260/280 ratio was calculated by spectrophotometer and used 
to evaluate the DNA purity (range between 1.8 and 2.0 was 
considered acceptable). Quantitative polymerase chain reaction 
(qPCR) for parasite quantification was performed using 100 ng 
of total DNA using a T. cruzi DNA dilution (standard curve). 
The standards for the qPCRs were generated using DNA from 
T. cruzi (Dm28c) epimastigotes. Considering that one parasite 
contains about 100  fg of DNA (46), we designed a curve with 
initial 2.5  ng (equivalent to 25,000 parasites with Ct-mean 19) 
and serially diluted (1:10) until the lower limit of 2.5  fg (0.025 
parasites with a Ct-mean 37). The reactions were performed in 
a StepOne sequence detection system (Applied Biosystems, 
Warrington, UK) using SYBR Green PCR Master Mix (Applied 
Biosystems, Warrington, UK). The standard PCR conditions 
were 95°C (10 min), and then 45 cycles of 95°C (30 seg), 60°C 
(1  min), followed by the standard denaturation curve. Each 
reaction contained DNA template and 0.4 µM of each T. cruzi-
specific primers GCTCTTGCCCACACGGGTGC (forward) 
and CCAAGCAGCGGATAGTTCAGG (reverse); and 0.1 µM of 
each primer for genomic B2m, CTGAGCTCTGTTTTCGTCTG 
(forward) and TATCAGTCTCAGTGGGGGTG (reverse). For 
quantification, T. cruzi measurement (average of triplicates) was 
corrected using the murine B2M-product (loading control, aver-
age of triplicates).
statistical analysis
Data are presented as mean ±  SD, unless otherwise indicated. 
The Student t-test and/or analysis of variance (ANOVA and 
Wilcoxon) were used to determine statistical significance. When 
the mean values of the groups showed a significant difference, 
pair-wise comparison was performed using the Bonferroni test. 
Statistical significance was set at P < 0.05. All statistical analysis 
was performed with Prism 5.0 (GraphPad Software).
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resUlTs
histamine and BK Potentiate the 
Proinflammatory Phenotype of TcTs
We have previously demonstrated that TCTs elicit plasma leakage 
via cooperation between tGPI, a mucin-linked phosphatidylino-
sitol anchor that activates toll-like receptor 2 (TLR2) (47, 48) and 
cruzipain, a cysteine protease that releases kinins from surface 
bound HK and C5a from native C5 (31). More recently, studies 
of the pathogenesis of anaphylaxis linked severe MC-mediated 
reactions to BK release via heparin-induced activation of the 
contact system (10). Given this precedent, and limited informa-
tion about the pathogenic role of MCs in Chagas disease (49, 50), 
we asked whether T. cruzi-induced inflammation was propagated 
via activation of the MC/KKS pathway. IVM in the HCP seemed 
to be an appropriate system to address this question because 
(i) MCs are predominantly positioned along arterioles of the 
HCP and respond to topically applied stimuli such as 48/80 (51), 
(ii) the pathogens are topically applied to the HCP (33), hence 
dispensing the use of needles—a procedure that causes bleeding 
and spurious KKS activation, and (iii) hamsters are susceptible to 
T. cruzi infection and exhibit a dilated chronic cardiomyopathy 
that closely resembles the human heart disease (52).
Before checking whether T. cruzi-induced inflammation 
involved activation of the MC/KKS pathway, we performed a 
series of mechanistic studies in a simplified model involving topic 
application of DXS (500 kDa)—a classical activator of the contact 
system (53), here used to simulate the effect of MC-derived triggers, 
such as heparin and polyP, both of which stored in MC granules 
(11, 12). Prior to the undertaking of IVM studies, we conduced 
test tube assays to verify whether addition of DXS (20  nM) to 
citrated hamster plasma activated the contact system, generat-
ing enzymatically active PKa. As previously shown with human 
plasma (42), we found (Figure 1A) that (i) DXS-treated hamster 
plasma promoted the hydrolysis of the BK flanking sequences of 
murine kininogen-1 and (ii) the enzymatic cleavage was inhibited 
by PKSI-527, a well-characterized PKa inhibitor (41).
Next, we checked whether the topically applied DXS (4 µM; 
added to the superfusate) could elicit plasma leakage (FITC-
dextran extravasation) in the HCP via activation of the KKS. 
Intriguingly, DXS did not evoke significant microvascular leakage 
for at least 30 min (Figure 1B, left panel). Unexpectedly, however, 
we noticed a subtle extravasation in a few postcapillary venules 
at later time-points (Figure 1B, left panel), which then rapidly 
propagated throughout the entire HCP. This delayed plasma 
leakage elicited by DXS (>30  min) was inhibited both by cro-
moglycate (Figure 1B, right panel, Figure S1 in Supplementary 
Material) and by HOE-140, a specific B2RA (Figure S1 in 
Supplementary Material). These initial results suggested that 
some extent of MC degranulation occurred after 30  min of 
HCP exposure to DXS 4  µM. Further downstream, histamine 
released from MCs could activate endothelial cells and, thus, 
enable diffusion of plasma-borne contact factors (FXII/PK/HK) 
through the DXS-laden HCP. Since these effects were blocked by 
HOE-140, we deduced that BK released at the downstream end 
of the proteolytic cascade could intensify and spatially propagate 
inflammation via iterative cycles of endothelial B2R activation, 
plasma leakage and MC degranulation. To test this hypothesis, 
we next checked whether addition of sub-optimal concentrations 
of DXS (10-fold lower; 0.4 µM) and histamine (4 µM, likewise 
added to the superfusate) could act synergistically in the HCP. 
Indeed, we saw a fourfold increase (P <  0.05) in the maximal 
extravasation of plasma induced by DXS/histamine at 10  min 
(Figure  1C) as compared to the microvascular leakage evoked 
by histamine alone (10 min). Moreover, the leakage induced by 
DXS/histamine was further potentiated by addition of captopril, 
i.e., inhibitor of BK degradation by ACE; the presence of the ACE 
inhibitor led to a 12-fold increase in maximal extravasation at 
20  min—as compared to histamine alone (10  min, Figure  1C, 
fold increase calculated after subtraction of the baseline fluores-
cence). Importantly, the synergistic effects of DXS/histamine were 
inhibited by (i) cromoglycate, irrespective of absence (Figure 1C) 
or presence (Figure  1C; Figure S3 in Supplementary Material) 
of captopril, (ii) HOE-140 (Figure  1D), (iii) the PKa inhibitor 
PKSI-527 (Figure 1D), and (iv) PdSP15a (Figure 1D), a contact 
phase inhibitor present in the saliva of the sand fly Phlebotomus 
duboscai (42). To further evaluate whether MC/histamine-driven 
influx of plasma was the rate-limiting step governing BK release 
in DXS-HCP, we substituted the histamine “priming” step by add-
ing an aliquot (50 µl) of fresh hamster plasma (heparinized) on 
top of the HCP. Prior to application on the tissue, we conducted 
the test tube assay described above (Figure 1C) and confirmed 
that there was no spontaneous activation of the contact system 
in the hamster plasma-treated with 4  kDa heparin. Moreover, 
the presence of heparin 4 kDa did not protect the plasma from 
PK activation by DXS (Figure S2 in Supplementary Material). 
As predicted, DXS promptly induced microvascular leakage via 
the kinin/B2R-dependent pathway (Figure 1E). Control experi-
ments revealed that the integrity of the endothelial barrier was 
preserved in HCP exposed to hamster plasma in the absence of 
DXS (Figure 1E).
In the next series of experiments (Figure 2), the TCTs were 
topically applied to the HCP jointly with a sub-optimal dose of 
histamine with the purpose to induce a subtle microvascular 
leakage in the parasite-laden tissues. As described in previous 
studies, the superfusion of the HCP is interrupted for a longer 
period (9  min) to allow for the diffusion/attachment of the 
motile flagellated parasites to the tissue stroma (see Methods). 
To minimize ACE/kininase II-dependent degradation of 
intact kinins during the period of interrupted superfusion, we 
routinely added the ACE inhibitor captopril to the superfusate 
(29, 31, 38). As predicted, the application of TCTs to histamine-
primed (suboptimal) HCPs induced leakage responses that 
were far more robust as compared to that induced separately 
by the pathogen or by histamine (Figure 2A, 328 and 1,094%, 
respectively, at 15 and 20 min; P < 0.014 and 0.037, percentage 
calculated after subtraction of the baseline fluorescence). The 
notion that TCTs/histamine acted synergistically at 15, 20, and 
25 min (Figure 2A; green versus black squares, P < 0.05) was 
confirmed by analysis of the arithmetic sum of leakage responses 
from individual hamsters to histamine alone and TCTs alone. 
Similarly, measurements of area under the curve (up to 30 min) 
FigUre 1 | Bradykinin-induced microvascular leakage is propagated via coupling of mast cell and contact phase factors. (a) Enzyme assays performed with high 
molecular weight kininogen mimetic substrate detect plasma kallikrein (PKa) activity in fresh hamster plasma (citrated) incubated with the contact activator dextran 
sulfate (DXS) (20 nM). The kinetics of hydrolysis was performed in the presence/absence of the PKa inhibitor PKSI-527. Substrate hydrolysis was monitored by the 
increase of fluorescence with time (mean ± SD). Data are representative of three independent experiments run in duplicates. (B–e) Microvascular leakage in the 
hamster cheek pouch (HCP) sensitized with DXS. (B) HCPs were superfused with DXS (4 µM) for 45 min and fluorescence was visualized at different time-points 
(representative images, n = 6). Where indicated, the hamsters were pretreated with cromoglycate. (c) Synergism between histamine and DXS was studied after 
30 min tissue superfusion, with medium supplemented with DXS 0.4 µM, in the presence or absence of captopril, followed by 5 min of histamine application, i.e., 
without any interruption of superfusion., DXS/Hist (n = 5), DXS/Capto/Hist (n = 5). Where indicated, the hamsters were pretreated i.p. with cromoglycate (n = 2, and 
n = 4, in the presence and absence of captopril, respectively). Histamine-induced leakage (n = 12) was inserted (internal controls) for comparison. (D) Evidence that 
synergism between DXS/histamine leads to leakage via activation of the kallikrein–kinin system was sought in HCP superfused for 10 min with DXS (2 µM) and 
captopril, followed by 5 min of superfusion with DXS/histamine application (n = 9). Prior to the application of histamine, the DXS-treated HCPs were either treated 
(superfusion interrupted) with the contact phase inhibitor PdSP15a (n = 6) or with PKa inhibitor PKSI-527 (n = 5) for 5 min. HOE-140 (n = 4) , the B2R antagonist 
(B2RA) was applied together with DXS + Captopril. (e) For plasma reconstitution experiments, HCPs were superfused with DXS + Captopril for 10 min, followed by 
topical application (superfusion interrupted) of heparinized hamster plasma for 7 min. Plasma (n = 5), and DXS/plasma (n = 8). HOE-140 (n = 4) was applied along 
with DXS + Captopril before addition of plasma. Data are expressed as: (c–e) Relative fluorescence units (RFUs) (mean ± SD). Statistical analyzes were done by 
analysis of variance and t-test. In (c), *P < 0.05 DXS/Capto/Hist versus DXS/Hist and +P < 0.05 for DXS/Hist versus DXS/Crom/Hist and D, *P < 0.05 DXS/
PdSP15a/Hist versus DXS/Hist.
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FigUre 2 | A subtle destabilization of the endothelial barrier potentiates 
infection-associated inflammation. (a–c) Hamster cheek pouches (HCPs) 
were superfused with captopril for 10 min, followed by application of 
histamine (4 µM) along with tissue culture trypomastigotes (TCTs) (3 × 107) 
during 10 min of interrupted superfusion (n = 12). TCT control group (n = 8) 
involved HCP treatment with captopril in the absence of histamine. Prior to 
TCT/histamine application, pharmacological interventions were performed 
with cromoglycate (pretreatment, n = 6); HOE-140 (B2RA; n = 5) and 
PKSI-527 (n = 5), applied for 5 min. In A at 60 min after TCT application 
histamine 4 µM (n = 8) was applied as an internal control and these values 
were then added to the TCT values (real sum – green curve) and used for the 
calculation of a synergistic effect of histamine and TCT. Results of histamine 
4 µM (n = 10) applied to HCPs in steady state were inserted as a secondary 
control. Data are expressed as follows: (a) relative fluorescence units (RFUs) 
over time (mean ± SD), (B) area under the curve (AUC ± SD) measured 
during 30 min. Statistical analysis were done by analysis of variance (ANOVA) 
and Wilcoxon. In (a) *P < 0.05 (TCT/Hist versus TCT) and +P < 0.05 (TCT/
Hist versus real sum). In (B) *P < 0.05 (TCT/Hist versus TCT or TCT/Hist/
inhibitor/antagonist) (c) HCPs were superfused with captopril for 10 min, 
followed by topical application of different doses of TCTs (60, 600, 6,000, 
and 60,000 TCTs/μl) and histamine (n = 4) during 10 min of interrupted 
superfusion (dark gray). At 60 min after TCT application, histamine was 
applied during 5 min as a control (light gray). Data are expressed as maximal 
increase in RFU (mean ± SD). Statistical analyzes were done by ANOVA and 
Wilcoxon (*P < 0.05, TCT/Capto/Hist versus histamine; TCT/Capto/Hist 
versus TCT; +P < 0.05, TCT 60/Capto/Hist versus TCT 6000/Capto/Hist).
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inhibitor PKSI-527 (Figure  2B, P  <  0.05). We reached the 
same conclusion using the peak of macromolecular leakage as 
the criteria (Figure S4 in Supplementary Material, P <  0.05). 
Control experiments, i.e., performed in the absence of TCTs, 
showed that plasma leakage induced by histamine alone (4 µM) 
was not potentiated by captopril, nor was it inhibited by HOE-
140, PKSI-527 or cromoglycate (Figure S5 in Supplementary 
Material). Finally, histamine-sensitized HCPs were topically 
exposed to decreasing doses of TCTs in order to determine 
the minimal load of pathogen that was capable of evoking a 
significant leakage. Our results (Figure 2C) showed that a 100-
fold lower load (corresponding to 600 TCTs/μl) still caused a 
statistically significant increase in plasma leakage (P <  0.05) 
as compared with histamine alone. Collectively, our studies 
suggest that tissues with leaking postcapillary venules might 
potentiate the proinflammatory phenotype of trypomastigotes 
via activation of BK-induced feedback loops forged by MC 
coupling to the KKS.
T. cruzi elicits Paw edema via activation 
of the Mc/KKs Pathway
Although the studies in the HCP provided a framework to inves-
tigate the impact of plasma leakage on the proinflammatory phe-
notype of T. cruzi, the anesthetized hamsters must be sacrificed 
at the end of the IVM experiments (~60 min), thus precluding an 
analysis of the pathogenic outcome at later time points. Turning 
to mice models of infection, we next injected Dm28c TCTs in the 
footpad of B6-KitW-sh/W-sh (MC-deficient) and B6-Kit+/+ mice. 
Edema measurements (3 h) revealed a prominent edema in WT 
mice (Figure 3A) and a negligible paw response in the mutant 
strain (Figure  3A). Internal controls in MC-competent mice 
showed that the edema was inhibited by HOE-140 (B2RA) (72%, 
P < 0.05) (Figure 3A). We next pretreated WT mice with cromo-
glycate, and found that this classical MC stabilizer inhibited the 
infection-associated edema (49%, P < 0.05) even in animals that 
received captopril (Figure  3B). Noteworthy, cromoglycate did 
not inhibit inflammation as efficiently as HOE-140 at this early 
time point (3 h) (Figure 3B, left panel) but the protective effects 
of these two drugs equalized at 24 h p.i. (Figure 3B, right panel). 
Similarly, mepyramine (antagonist of histamine H1 receptor, 
H1RA) partially inhibited TCT-evoked swelling both at 3 and 24 h 
p.i. (67%, P < 0.05, and 83%, P < 0.05, respectively; Figure 3B). 
To verify whether TCTs evoked B2R-dependent edema via MC 
coupling to the contact system, we next pretreated BALB/c mice 
with infestin-4, a recombinant protein recently characterized as 
a specific inhibitor of FXIIa (36). Indeed, infestin-4 drastically 
inhibited TCT-induced swelling (75%, P <  0.05) (Figure  3C), 
thus further suggesting that activation of the BK/B2R pathway 
propagates the inflammatory response orchestrated via the 
contact pathway.
intracardiac activation of the Mc/KKs 
Pathway Fuels heart Parasitism and 
infection-associated Myocarditis/Fibrosis
Given pieces of evidence that BRs and ETRs serve as gateways 
for T. cruzi invasion of cardiovascular cells in vitro (13, 27, 33), 
showed that the spatial propagation of inflammation observed 
in histamine-primed HCPs exposed to TCTs was abolished by: 
(i) B2RA (HOE-140), (ii) cromoglycate, and (iii) the PKa 
FigUre 3 | Tissue culture trypomastigotes (TCTs) evoke paw edema via the mast cell (MC)/kallikrein–kinin system pathway. (a) WT (B6-Kit+/+) or MC-deficient mice 
(B6-kitW-sh/W-sh) were infected with TCTs (106). The contralateral paw received PBS. When indicated, mice were pretreated (−1 h) with the B2R antagonist (B2RA) 
(HOE-140). (B,c) Infected BALB/c mice were pretreated (−1 h) with HOE-140, cromoglycate (MC stabilizer), histamine H1 receptor (H1R) antagonist (mepyramine) 
or factor XII (FXII) inhibitor (infestin-4). Captopril was used (i.p.) to inhibit kinin degradation. Edema was measured at 3 and 24 h and results are expressed as 
difference in volume (μl) between infected and contralateral paw (mean ± SD). Data are representative of three independent experiments (five mice/group). Statistical 
analyzes were done by analysis of variance with Bonferroni post test (*P < 0.05; **P < 0.01, ***P < 0.001).
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here we asked whether intracardiac activation of the MC/KKS 
pathway could promote parasite infectivity by fostering the 
proteolytic release of kinins and endothelins, which could then 
act as infection-promoting signals in heart tissues. Assisted by 
high-resolution echocardiography, we injected TCTs (Dm28c) 
directly in the LV of the heart of WT and MC-deficient mice. 
Heart parasite load (replicating amastigotes) was evaluated 
3 d.p.i. by quantifying T. cruzi DNA by qPCR. In the second 
group of experiments, intracardiac challenge with TCTs was 
performed in WT mice that were pretreated 1  h earlier with 
(i) cromoglycate, (ii) infestin-4, (iii) HOE-140, and (iv) bosentan 
(double antagonist of ETAR/ETBR). Noteworthy, here (unlike the 
experimental conditions used in the footpad model of infection), 
the animals were not pretreated with captopril—thus preserving 
the kinin-degrading function of ACE as well as its competence 
to convert angiotensin I into the vasoconstrictor angiotensin II 
in the cardiovascular system. At different time-points (see time-
line, Figure 4), we examined extent of heart parasitism (3 d.p.i.) 
and pathological outcome (histopathology, 30 d.p.i.). Strikingly, 
we observed that the parasite load in heart tissues declined 
in WT mice pretreated by HOE-140 (B2RA) (Figures  4A,D; 
respectively 71 and 76%, P <  0.001) or bosentan (ETAR/ETBR 
Antag, Figure 4A, 80%, P < 0.001). Having established that these 
GPCR blockers redundantly inhibited intracardiac parasitism in 
WT mice, we next asked whether cardiac MCs were implicated 
in this process. First, we compared the levels of parasite DNA 
in the heart of MC-deficient B6-KitW-sh/W-sh mice versus 
MC-competent mice. Notably, the parasite load (3 d.p.i.) was 
sixfold lower in the hearts of the MC-deficient strain as com-
pared to the WT controls (Figure 4B). Given technical difficul-
ties to reconstitute the heart of MC-deficient mice with bone 
marrow-derived progenitor cells, we re-addressed this question 
by subjecting WT mice to pharmacological treatment with the 
MC stabilizer cromoglycate. Consistent with the protective 
phenotype of MC-deficient mice, we found that heart parasitism 
(Figure 4C) was sharply reduced in cromoglycate-treated mice 
(78%, P <  0.05). Noteworthy, control experiments performed 
with cromoglycate (tested in vitro at a concentration equivalent 
to that present in the bloodstream) confirmed that this MC sta-
bilizer did not impair T. cruzi infection of primary mouse heart 
cells (Figure S6 in Supplementary Material). We next pretreated 
WT mice with the FXIIa inhibitor infestin-4 and verified that the 
intracardiac levels of T. cruzi DNA (Figure 4D; 97%, P < 0.01) 
were sharply decreased.
Next, we performed histopathological studies to determine 
whether the early cardioprotective effects promoted by the 
GPCR antagonists attenuated heart pathology. Not surprisingly, 
histopathology performed at 30 d.p.i. revealed that myocarditis/
fibrosis was intense in the control infected mice (Figure  5). 
Interestingly, the elevated infiltration of leukocytes in chagasic 
mice was accompanied by increased density of intracardiac 
MCs (Figure 5). Strikingly, we found a significant reduction in 
the numbers of heart-inflammatory infiltrating leukocytes and 
of density of intracardiac MCs in T. cruzi-infected mice pre-
treated with B2RA (HOE-140) or ETAR/ETBR Antag. (bosentan) 
(Figure  5A, leukocytes; respectively, 34%, P <  0.05; and 82%, 
P < 0.001-MC density; respectively, 45%, P < 0.01; 80%, P < 0.01; 
Figure 5B). Examination of heart fibrosis at the same time-points 
again confirmed that these GPCR antagonists were redundantly 
cardioprotective: the deposition of collagen was markedly attenu-
ated in mice pretreated either with B2RA or with the double 
ETAR/ETBR blocker (Figure 5C, respectively 73%, P < 0.05; 85%, 
P < 0.05). Collectively, our studies suggest that excessive intracar-
diac activation of the MC/KKS pathway fueled T. cruzi parasitism 
and worsened myocarditis/fibrosis via proteolytic generation of 
kinins and endothelins.
FigUre 4 | Activation of the kallikrein–kinin system fuels heart parasitism. Measurements of Trypanosoma cruzi DNA (3 d.p.i.) in the heart of C57BL/6 infected [106 
tissue culture trypomastigotes (TCTs)] intracardiacally (a,c,D), WT (B6-Kit+/+) mice or mast cell deficient (B6-kitW-sh/W-sh) mice (B). Where indicated, the mice were 
pretreated with cromoglycate, B2R antagonist (B2RA) (HOE-140), endothelin A receptor (ETAR)/endothelin B receptor (ETBR) double antagonist (bosentan) or factor 
XII (FXII) inhibitor (infestin-4). Results (mean ± SD) of T. cruzi DNA by quantitative polymerase chain reaction (qPCR) are representative of two independent 
experiments (five mice/group). Statistical analyzes were done by analysis of variance with Bonferroni post test (*P < 0.05; **P < 0.01, ***P < 0.001).
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DiscUssiOn
Standard definitions of immune subversion are built on the 
assumption that pathogens exploit host cell metabolism and shifts 
in immunoregulatory responses to survive in hostile environ-
ment. Although we have previously demonstrated that activation 
of the proinflammatory kinin/B2R pathway generates immuno-
protective IFN-γ-producing effector T cells against T. cruzi (30), 
here we provide evidence that T. cruzi reciprocally benefits from 
the intracardiac activation of the MC/KKS pathway: acting jointly 
with endothelins, kinins enhance tissue parasitism via activation 
of B2R.
Since chronic Chagas disease last several years, occasional 
fluctuations in immunoregulation may favor intracellular para-
site outgrowth in scattered heart cells. Sporadically, a few heavily 
parasitized host cells rupture, swarming the surrounding tissues 
with infective trypomastigotes. Within minutes, the endothelial 
barrier might open in response to endogenous alarmins and/or 
proinflammatory molecules shed from the trypomastigote surface 
(Figure 6). It is still unclear whether the genetic diversification 
of the T. cruzi species contributes to the clinical pleiomorphism 
of CCC (54). Of interest in this context, the expression levels of 
proinflammatory galactosyl-bearing lipid anchors (55) vary 
within the genetically diversified T. cruzi species. In previous 
studies performed with the Dm28c strain (29, 31, 33, 38), we 
demonstrated that Dm28c TCTs (but not avirulent Dm28c epi-
mastigotes) evoke a subtle endothelial barrier destabilization via 
a trans-cellular activation pathway (TLR2/CXCR2/ETAR/ETBR/
B2R/C5aR) initiated by tGPI (TLR2 ligand) and amplified by the 
kinin-releasing activity of cruzipain (see scheme on Figure 6). In 
this paper, we showed evidence that the trans-endothelial diffu-
sion of plasma—here sought through the activation of the MC/
KKS pathway—enhances both the proinflammatory phenotype 
and infectivity of Dm28c TCTs. In order to simulate tissues 
irrigated by “leaky” microvessels, we added sub-optimal doses of 
histamine jointly with the topically applied TCTs. As predicted, 
the microvascular leakage response evoked by TCTs was potenti-
ated by BK-induced inflammatory cascades coordinated via the 
MC/KKS pathway. Although the roles of MC-derived polyP/
heparin were not directly investigated here, the mechanistic 
insight that inspired this study came from simplified model stud-
ies performed with DXS, a potent activator of the contact system 
(53). Unexpectedly, the topically applied DXS did not induce any 
microvascular alterations in steady-state HCP for at least 30 min; 
thereafter, however, a few localized “leaks” appeared, triggering 
a MC/KKS (contact phase) driven inflammatory response that 
rapidly spread throughout the HCP. Combined, the IVM stud-
ies with DXS and TCTs support a linear model of BK-induced 
opening of the endothelial barrier initiated by a subtle influx of 
plasma contact factors. Assays performed with different contact 
phase inhibitors suggest that BK, once liberated by PKa, triggers 
iterative cycles of endothelial (B2R) activation, plasma leakage, 
MC degranulation, and PolyP/heparin-induced activation of 
contact factors (Figure 6).
FigUre 5 | Early targeting of BRs and ETRs inhibit myocarditis/fibrosis. C57BL/6 mice were infected intracardiacally with tissue culture trypomastigotes (TCTs)  
(106) or PBS (mock). Where indicated, mice were pretreated with B2R antagonist (B2RA) (HOE-140), or endothelin A receptor (ETAR)/endothelin B receptor (ETBR) 
antagonist (bosentan). At 30 d.p.i., heart sections were stained with (a) hematoxylin and eosin for cellular infiltration, (B) Safranin for mast cell detection, or  
(c) Picrosirius Red for collagen deposition. Bars, 50 µm. Data (mean ± SD) are representative of four independent experiments (five mice/group). Statistical analyzes 
were done by analysis of variance (*P < 0.05; **P < 0.01, ***P < 0.001).
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In the second part of this paper, we studied the pathogenic 
role of the MC/KKS pathway using two different mouse models 
of infection. Congruent with the IVM data generated in the 
HCP, we first showed that TCTs induced footpad edema via 
activation of BK/B2R-inflammatory cascades (orchestrated 
via the MC/KKS pathway). Extending these studies to the 
cardiac settings, we next inoculated TCTs in the heart of WT or 
MC-deficient mice and measured T. cruzi DNA levels at 3 d.p.i. 
These experiments revealed that intracardiac parasitism was 
markedly reduced in MC-deficient mice or, alternatively, in car-
diac tissues of WT mice pretreated either with (i) cromoglycate 
(ii) infestin-4 (iii) HOE-140 or (iv) bosentan (non-selective 
ETAR/ETBR antagonist). Based on these findings, we inferred that 
targeting of the MC/KKS pathway stabilized the endothelial bar-
rier, hence ultimately reducing the levels of infection-promoting 
signals (kinins and endothelins) generated in the parasite-laden 
heart tissues (Figure 6). It remains to be determined whether the 
GPCR blockers HOE-140 and bosentan inhibited parasite infec-
tivity by acting as endothelial barrier stabilizers, and/or acted 
further downstream, directly blocking GPCR-mediated uptake of 
TCTs (Figure 6) as originally documented in culture systems (13, 
27, 32, 33). Another possibility is that T. cruzi infection is fueled 
by ROS (56), presumably reflecting synergism between innate 
immunity (TLR2/CXCR2 pathway) (38) and the short-lived 
proinflammatory polypeptides generated further downstream, 
such as kinins and ET-1. The latter hypothesis is consistent with 
FigUre 6 | Endothelial barrier breakdown via the mast cell (MC)/kallikrein–kinin system (KKS) pathway fuels Trypanosoma cruzi infectivity: working hypothesis. (1) 
Tissue culture trypomastigotes liberated from ruptured pseudocysts initiate inflammation upon sensing by toll-like receptor 2 (TLR2)-expressing tissue macrophages. 
(2) Secreted CXC chemokines evoke a subtle plasma leakage following CXCR2-dependent activation of endothelium/neutrophils (29, 38); although not explored in 
this infection model, it has been reported that TNF-α (57) is critically involved in neutrophil-evoked plasma leakage. (3) The diffusion of plasma proteins, including 
native C5 and kininogens, leads to cruzipain-mediated release of kinins and C5a anaphylatoxin in the parasite-laden tissues (31). (4) Results presented in the current 
work suggest that cardiac MCs activated by C5a and/or endothelin-1 (not shown in this part of the illustration) release histamine/polyphosphates (PolyP) (contact 
system activators) from their granules. (5) Activation of histamine H1 receptor (H1R) leads to the exposure of plasma-borne contact factors [factor XII (FXII), high 
molecular weight kininogen (HK) and plasma prekallikrein] to heparin/PolyP. Further downstream, the activated contact factor plasma kallikrein (PK) releases 
bradykinin (BK) from HK. (6) BK propagates the leakage response temporally and spatially via iterative cycles of endothelial [bradykinin B2 receptor (B2R)] activation 
(BK/B2R pathway), plasma leakage, MC degranulation, and contact system activation (MC/KKS pathway). (7) Acting jointly with endothelin-1 (ET-1), the released 
kinins fuel T. cruzi infectivity by signaling heart cells that naturally overexpress B2R (13) and ETAR/endothelin B receptor (ETBR) (33). (8) After endocytic internalization, 
the flagellated trypomastigotes transform into amastigotes which undergo multiple cycles of binary division in the host cell cytoplasm before transforming into 
infective trypomastigotes.
12
Nascimento et al. MC-BK Pathway in Chagas Disease
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 840
the view that plasma membrane lesions evoked by ROS (fueled 
by kinins and endothelins) might trigger a house-keeping mecha-
nism of membrane repair (Ca2+/acid sphingomyelinase/ceramide 
pathway) that drives T. cruzi internalization into ceramide-rich 
endocytic vesicles—as originally proposed by Ref. (45).
Although not addressed here, it will be interesting to deter-
mine whether parasitized heart cells in our intracardiac model 
of infection upregulate ET-1 expression in our controls (i.e., in 
the absence of pharmacological intervention on the MC/KKS 
pathway) as documented in conventional models of Chagas 
heart disease (26). If confirmed, it will be necessary to evaluate 
whether ET-1 secretion in T. cruzi-infected heart tissues depends 
on the innate recognition of intracellular parasites (amastigotes). 
In principle, this mechanism may either involve (i) TLR9, 
recently defined as a sensor of unmethylated CpG motifs of 
T. cruzi DNA (58) (ii) TLR7, activated by parasite-derived RNA 
(59) and/or activation of NLRP3 inflammassome (60).
Lessons coming from studies of innate immunity in models 
of heart injury induced by pressure overload (61) might provide 
clues to understand the mechanism underlying the cardioprotec-
tive effects of GPCR blockers documented in our study. Using 
DNAse II-deficient mice, the above-mentioned authors verified 
that, under these stressful conditions, the excessive accumulation 
of host mitochondrial DNA (symbiont-like) in autolysosomes 
upregulates inflammation via activation of TLR9. In principle, 
it is possible that TLR9-dependent sensing of T. cruzi DNA 
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(amastigotes) might upregulate ET-1 secretion. In mice pre-
treated with HOE-140 or bosentan, the intracardiac load of T. 
cruzi parasites was markedly reduced. Thus, it is conceivable that 
the pharmacological targeting of the MC/KKS pathway reduced 
intracardiac inflammation and tissue parasitism to levels that are 
beyond the threshold required to upregulate ET-1 via activation 
of innate receptors. Consistent with this viewpoint, studies of 
MC function in other models of heart inflammatory diseases 
appointed cardiac MCs as central player in cardiac remodeling 
(62). Our findings that the density of intracardiac MCs (30 d.p.i.) 
was increased in mice subjected to intracardiac challenge with 
T. cruzi is congruent with clinical evidence showing that (i) MC 
density is increased in heart tissues from HIV-reactivated CCC 
patients (63). Although our intracardiac model of (acute) infec-
tion is admittedly artificial, it was surprising that severity of myo-
carditis and heart fibrosis in WT mice (evaluated at 30 d.p.i.) was 
blunted in animals that were pretreated either with B2R or ETAR/
ETBR antagonists. Intriguingly, the density of cardiac MCs was 
also reduced in WT mice that were subjected to the single-dose 
treatment with these GPCR blockers at the time of intracardiac 
challenge. Combined, these results suggest that endothelins/
kinins, acting jointly, might upregulate trans-endothelial migra-
tion of MC precursors and/or enhance MC maturation following 
recruitment to the parasitized heart tissues. Future studies may 
clarify whether cardiac MCs activated by ET-1 may intercon-
nect intracellular innate responses (orchestrated by TLRs and/
or inflammassome) to the proteolytic circuitry that propagates 
inflammation and heart fibrosis via the KKS. While these patho-
genic processes are in march in chagasic patients, it is possible 
that the sporadic formation of inflammatory edema may provide 
T. cruzi trypomastigotes with an opportunity to invade heart cells 
that naturally overexpress bradykinin and endothelin receptors. 
In summary, by studying the impact infection-associated micro-
vascular leakage on the pathogenesis of T. cruzi infection, our 
study provides a new mechanistic framework to investigate the 
role of proteolytic networks, such as the KKS, on host/parasite 
balance in Chagas heart disease.
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